Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $12
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target from $18 to $12.
Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target from $18 to $12.